BRPI0915887A2 - derivados de indol macrocíclicos úteis como inibidores do vírus da hepatite c - Google Patents

derivados de indol macrocíclicos úteis como inibidores do vírus da hepatite c

Info

Publication number
BRPI0915887A2
BRPI0915887A2 BRPI0915887A BRPI0915887A BRPI0915887A2 BR PI0915887 A2 BRPI0915887 A2 BR PI0915887A2 BR PI0915887 A BRPI0915887 A BR PI0915887A BR PI0915887 A BRPI0915887 A BR PI0915887A BR PI0915887 A2 BRPI0915887 A2 BR PI0915887A2
Authority
BR
Brazil
Prior art keywords
hepatitis
indole derivatives
derivatives useful
virus inhibitors
macrocyclic indole
Prior art date
Application number
BRPI0915887A
Other languages
English (en)
Inventor
Abdellah Tahri
Katie Ingrid Eduard Amssoms
Pierre Jean-Marie Bernard Raboisson
Sandrine Marie Hélène Vendeville
Tse-I Lin
Original Assignee
Tibotec Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tibotec Pharm Ltd filed Critical Tibotec Pharm Ltd
Publication of BRPI0915887A2 publication Critical patent/BRPI0915887A2/pt
Publication of BRPI0915887B1 publication Critical patent/BRPI0915887B1/pt
Publication of BRPI0915887B8 publication Critical patent/BRPI0915887B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D515/18—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BRPI0915887A 2008-07-08 2009-07-08 derivados de indol macrocíclicos úteis como inibidores do vírus da hepatite c BRPI0915887B8 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP08159965.6 2008-07-08
EP08159965 2008-07-08
EP08160254.2 2008-07-11
EP08160254 2008-07-11
EP08161743 2008-08-04
EP08161743.3 2008-08-04
PCT/EP2009/004942 WO2010003658A1 (en) 2008-07-08 2009-07-08 Macrocyclic indole derivatives useful as hepatitis c virus inhibitors

Publications (3)

Publication Number Publication Date
BRPI0915887A2 true BRPI0915887A2 (pt) 2015-11-03
BRPI0915887B1 BRPI0915887B1 (pt) 2020-02-18
BRPI0915887B8 BRPI0915887B8 (pt) 2021-05-25

Family

ID=40972916

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0915887A BRPI0915887B8 (pt) 2008-07-08 2009-07-08 derivados de indol macrocíclicos úteis como inibidores do vírus da hepatite c

Country Status (32)

Country Link
US (2) US8921355B2 (pt)
EP (1) EP2310396B1 (pt)
JP (2) JP5426671B2 (pt)
KR (1) KR101640374B1 (pt)
CN (1) CN102089314B (pt)
AP (1) AP2743A (pt)
AR (1) AR072726A1 (pt)
AU (1) AU2009267389B8 (pt)
BR (1) BRPI0915887B8 (pt)
CA (1) CA2729307C (pt)
CL (1) CL2011000032A1 (pt)
CO (1) CO6351793A2 (pt)
CR (1) CR20110076A (pt)
DK (1) DK2310396T3 (pt)
EA (1) EA019008B1 (pt)
EC (1) ECSP11010750A (pt)
ES (1) ES2651038T3 (pt)
HK (1) HK1155734A1 (pt)
HN (1) HN2011000072A (pt)
HR (1) HRP20171892T1 (pt)
HU (1) HUE035244T2 (pt)
IL (1) IL210086A (pt)
LT (1) LT2310396T (pt)
MX (1) MX2011000276A (pt)
NI (1) NI201100010A (pt)
NO (1) NO2310396T3 (pt)
NZ (2) NZ590073A (pt)
SI (1) SI2310396T1 (pt)
SV (1) SV2011003796A (pt)
TW (1) TWI454476B (pt)
UY (1) UY31973A (pt)
WO (1) WO2010003658A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2238142T3 (da) 2007-12-24 2012-10-08 Janssen R & D Ireland Makrocykliske indoler som hepatitis C-virusinhibitorer
TWI454476B (zh) * 2008-07-08 2014-10-01 Tibotec Pharm Ltd 用作ｃ型肝炎病毒抑制劑之巨環吲哚衍生物
UA108211C2 (uk) * 2009-11-04 2015-04-10 Янссен Рід Айрленд Бензімідазолімідазольні похідні
NZ602552A (en) * 2010-04-13 2014-09-26 Janssen Pharmaceuticals Inc Combination of a macrocyclic inhibitor of hcv, a non-nucleoside and a nucleoside
US9127010B2 (en) 2010-06-24 2015-09-08 Janssen Sciences Ireland Uc Preparation of 13-cyclohexyl-3-methoxy-6-[methyl-(2-{2-[methyl-(sulphamoyl)-amino]-ethoxy}-ethyl)-carbamoyl]-7H-indolo-[2,1-a]-[2]-benzazepine-10-carboxylic acid
CN103842330B (zh) 2011-09-02 2016-10-19 诺华股份有限公司 抗炎的取代的环丁烯二酮化合物的胆碱盐
US8716275B2 (en) * 2011-10-20 2014-05-06 Bristol-Myers Squibb Company Compound for the treatment of hepatitis C
US20150209366A1 (en) 2012-08-31 2015-07-30 Janssen Pharmaceuticals, Inc. Combination of a macrocyclic protease inhibitor of hcv, a non-nucleoside hcv inhibitor and ritonavir
WO2014152275A1 (en) * 2013-03-14 2014-09-25 Concert Pharmaceuticals, Inc. Deuterium modified derivatives of the ns5b polymerase inhibitor tmc647055
US10450263B2 (en) 2017-02-10 2019-10-22 Southern Research Institute Benzo annulenes as antiviral agents
KR101974388B1 (ko) 2017-06-23 2019-05-02 (주)에니켐텍 알킬 디에틸렌 트리아민 유도체 및 이의 제조방법
US11066357B2 (en) 2017-12-26 2021-07-20 Southern Research Institute Benzoannulene derivatives as antiviral agents

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6037157A (en) 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
US5807876A (en) * 1996-04-23 1998-09-15 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
US6054472A (en) * 1996-04-23 2000-04-25 Vertex Pharmaceuticals, Incorporated Inhibitors of IMPDH enzyme
US20050267836A1 (en) 1996-03-25 2005-12-01 Cfph, Llc Method and system for transacting with a trading application
EP0902782A1 (en) 1996-04-23 1999-03-24 Vertex Pharmaceuticals Incorporated Urea derivatives as inhibitors of impdh enzyme
DK0966465T3 (da) 1997-03-14 2003-10-20 Vertex Pharma Inhibitorer af IMPDH-enzymer
CN1196687C (zh) 1999-03-19 2005-04-13 沃泰克斯药物股份有限公司 Impdh酶抑制剂
KR100891240B1 (ko) 2000-08-30 2009-04-01 파나소닉 주식회사 플라즈마 디스플레이 표시장치 및 그 제조방법
CA2552319C (en) 2004-01-30 2012-08-21 Medivir Ab Hcv ns-3 serine protease inhibitors
US7153848B2 (en) * 2004-08-09 2006-12-26 Bristol-Myers Squibb Company Inhibitors of HCV replication
PE20070211A1 (es) 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
CA2620777A1 (en) 2005-09-02 2007-03-08 Tibotec Pharmaceuticals Ltd. Benzodiazepines as hcv inhibitors
US7399758B2 (en) * 2005-09-12 2008-07-15 Meanwell Nicholas A Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
GB0522881D0 (en) 2005-11-10 2005-12-21 Angeletti P Ist Richerche Bio Therapeutic compounds
WO2007092000A1 (en) 2006-02-06 2007-08-16 Bristol-Myers Squibb Company Inhibitors of hcv replication
US7521443B2 (en) 2006-05-17 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7456166B2 (en) * 2006-05-17 2008-11-25 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7521441B2 (en) * 2006-05-22 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
WO2007140200A2 (en) * 2006-05-25 2007-12-06 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
AU2007306405A1 (en) 2006-10-10 2008-04-17 Medivir Ab HCV nucleoside inhibitor
AU2007335962B2 (en) * 2006-12-20 2012-09-06 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Antiviral indoles
WO2009010785A1 (en) * 2007-07-17 2009-01-22 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Macrocyclic indole derivatives for the treatment of hepatitis c infections
TWI454476B (zh) * 2008-07-08 2014-10-01 Tibotec Pharm Ltd 用作ｃ型肝炎病毒抑制劑之巨環吲哚衍生物
TW201023858A (en) 2008-09-18 2010-07-01 Ortho Mcneil Janssen Pharm Synergistic combinations of a macrocyclic inhibitor of HCV and a nucleoside
LT2401272T (lt) 2009-02-27 2017-03-27 Janssen Pharmaceuticals, Inc. Hcv makrociklinio slopiklio amorfinė druska
NZ602552A (en) 2010-04-13 2014-09-26 Janssen Pharmaceuticals Inc Combination of a macrocyclic inhibitor of hcv, a non-nucleoside and a nucleoside
US9127010B2 (en) 2010-06-24 2015-09-08 Janssen Sciences Ireland Uc Preparation of 13-cyclohexyl-3-methoxy-6-[methyl-(2-{2-[methyl-(sulphamoyl)-amino]-ethoxy}-ethyl)-carbamoyl]-7H-indolo-[2,1-a]-[2]-benzazepine-10-carboxylic acid
US20150209366A1 (en) 2012-08-31 2015-07-30 Janssen Pharmaceuticals, Inc. Combination of a macrocyclic protease inhibitor of hcv, a non-nucleoside hcv inhibitor and ritonavir

Also Published As

Publication number Publication date
HN2011000072A (es) 2013-09-01
EA019008B1 (ru) 2013-12-30
US9427440B2 (en) 2016-08-30
JP2011527299A (ja) 2011-10-27
SV2011003796A (es) 2011-04-08
CA2729307C (en) 2017-08-29
US20110105473A1 (en) 2011-05-05
HK1155734A1 (en) 2012-05-25
AP2010005521A0 (en) 2010-12-31
IL210086A0 (en) 2011-02-28
CA2729307A1 (en) 2010-01-14
US8921355B2 (en) 2014-12-30
BRPI0915887B8 (pt) 2021-05-25
BRPI0915887B1 (pt) 2020-02-18
JP5426671B2 (ja) 2014-02-26
NI201100010A (es) 2011-09-07
AU2009267389B8 (en) 2013-07-04
CR20110076A (es) 2011-11-10
SI2310396T1 (en) 2018-01-31
UY31973A (es) 2010-01-29
KR101640374B1 (ko) 2016-07-18
JP2014028818A (ja) 2014-02-13
CN102089314A (zh) 2011-06-08
LT2310396T (lt) 2017-12-27
AP2743A (en) 2013-09-30
AU2009267389A8 (en) 2013-07-04
KR20110040889A (ko) 2011-04-20
NZ603343A (en) 2013-08-30
CN102089314B (zh) 2014-07-23
IL210086A (en) 2014-05-28
EA201170153A1 (ru) 2011-08-30
TWI454476B (zh) 2014-10-01
WO2010003658A1 (en) 2010-01-14
DK2310396T3 (en) 2017-12-11
JP5808370B2 (ja) 2015-11-10
ES2651038T3 (es) 2018-01-23
AU2009267389A1 (en) 2010-01-14
CO6351793A2 (es) 2011-12-20
HRP20171892T1 (hr) 2018-01-12
EP2310396B1 (en) 2017-09-06
TW201014865A (en) 2010-04-16
NZ590073A (en) 2012-11-30
NO2310396T3 (pt) 2018-02-03
EP2310396A1 (en) 2011-04-20
CL2011000032A1 (es) 2011-07-15
MX2011000276A (es) 2011-03-02
ECSP11010750A (es) 2011-08-31
US20140107101A1 (en) 2014-04-17
AR072726A1 (es) 2010-09-15
HUE035244T2 (hu) 2018-05-02
AU2009267389B2 (en) 2013-05-30

Similar Documents

Publication Publication Date Title
BRPI0915887A2 (pt) derivados de indol macrocíclicos úteis como inibidores do vírus da hepatite c
BRPI0821836A2 (pt) Indóis macrocíclicos como inibidores do vírus da hepatite c
BR112012002508A2 (pt) derivados de feniletinila como inibidores de vírus de hepatite c
ES2643164T3 (es) Indol 7-sustituido como inhibidores de Mcl-1
EP2621931A4 (en) TETRACYCLIC INDOLATE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTION
BRPI0908240A2 (pt) inibidores do vírus da hepatite c
BRPI0907733A2 (pt) Inibidores do vírus da hepatite c
BRPI0906625A2 (pt) Derivados de tio-2-amino-quinolina-6-substituída úteis como inibidores da beta-secretase (bace)
BRPI0820085A2 (pt) compostos contendo quinoxalina como inibidores de vírus da hepatite c
BRPI0911444A2 (pt) benzoimidazóis como inibidores de prolil hidroxilase
BRPI1013393A2 (pt) inibidores do vírus da hepatite c
BRPI1007836A2 (pt) Inibidores do vírus c da hepatite
BRPI0820236A2 (pt) Derivados de piridazinona como inibidores parp
BRPI0922912A2 (pt) peptídeos de 4-amino-4-oxobutanoil como inibidores de replicação viral
BRPI0923497A2 (pt) derivados de piridazinona
BRPI0913832A2 (pt) derivados de pirrolopiridinilpirimidin-2-ilamina
BRPI0915064A2 (pt) derivados de qunoxalinadiona
BRPI0809221A2 (pt) indol carboxamidas como inibidores de ikk2
BRPI0914942A2 (pt) Compostos de oxindol
BR112013002122A2 (pt) derivados hetero-bicíclicos como inibidores de hcv
BRPI0912234A2 (pt) derivados de salinosporamida como inibidores de proteassomas
BRPI0913234A2 (pt) derivados de tiazolilpiperidina
BRPI1012852A2 (pt) derivados de benzoxazolona como inibidores da sintase de aldoesterona
BR112013013037A2 (pt) derivados de indol como moduladores dos receptores de s1p
BRPI0922652A2 (pt) Derivados de quinazolinamida

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: JANSSEN R AND D IRELAND (IE)

B25A Requested transfer of rights approved

Owner name: JANSSEN SCIENCES IRELAND UC (IE)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 18/02/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 08/07/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF